Anuh Pharma Reports Strong Sales Growth Amid Declining Profitability in March 2025 Results

Anuh Pharma, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's evaluation, with the score moving to -1 from -10 over the past three months.
The financial data reveals that Anuh Pharma achieved its highest quarterly net sales in the last five quarters, reaching Rs 198.14 crore. This figure represents a growth of 26.4% compared to the average net sales of the previous four quarters, which stood at Rs 156.82 crore. Additionally, the profit before tax (PBT) for the quarter was recorded at Rs 15.88 crore, reflecting a growth of 20.8% against the average PBT of Rs 13.14 crore from the prior four quarters.

However, not all aspects of the financial performance are favorable. The profit after tax (PAT) for the latest six months was reported at Rs 22.80 crore, which shows a decline of 33.86% year on year. This indicates a contrasting trend in profitability compared to the positive sales and PBT growth.

For further insights into Anuh Pharma's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.